Heparin-Induced Thrombocytopenia in COVID-19

Area of Science:

• Hematology
• Infectious Diseases
• Critical Care Medicine

Background:

• COVID-19 (coronavirus disease-2019) is characterized by a hypercoagulable state, increasing the risk of thromboembolic events.
• Heparin therapy is frequently used for thromboprophylaxis in COVID-19 patients, but carries the risk of Heparin-induced thrombocytopenia (HIT).
• HIT is a life-threatening immune-mediated complication of heparin exposure, leading to thrombocytopenia and thrombosis.

Observation:

• A 63-year-old male with COVID-19 developed deep venous thrombosis and was initiated on therapeutic anticoagulation.
• During hospitalization, the patient experienced a significant drop in platelet count, raising suspicion for HIT.
• Clinical assessment using the 4T score and laboratory tests (anti-PF4/heparin antibody) indicated a high probability of HIT.

Findings:

• The patient's platelet count decreased from 304,000 to 96,000 cells/µL within 24 hours.
• Heparin was discontinued and replaced with argatroban, leading to a positive serotonin release assay confirming HIT.
• The study also notes potential overdiagnosis of HIT in COVID-19 patients due to false-positive antibody tests.

Implications:

• This case underscores the importance of vigilant monitoring for HIT in COVID-19 patients receiving heparin.
• Early recognition and prompt management, including switching to alternative anticoagulants like argatroban, are critical for patient outcomes.
• Further research is needed to differentiate true HIT from false-positive results in the context of COVID-19 infection.